Dr. Davide Corti obtained his bachelor in Pharmaceutical Biotechnology at the University of Milan and his Ph.D. in Immunology at the University of Bern, followed by postdoctoral training in Antonio Lanzavecchia's laboratory at the Institute for Research in Biomedicine where he further developed and optimized two methods for the isolation of human monoclonal antibodies out of memory B cells and plasma cells (Cellclone technologies).
In 2009 he was the Chief Scientific Officer at Humabs, where he leads a research group to isolate monoclonal antibodies against multiple infectious disease viral and bacterial agents.
Starting from 2012 he collaborated with MedImmune on the isolation of human antibodies against multiple target pathogens like Rhinovirus, Influenza B, Klebsiella and Staphylococcus.
His teams' efforts to date have generated three clinical stage candidates, MEDI8852 targeting Influenza A, mAb114 targeting Ebola virus and anti-CMV antibodies.
Dr. Corti has published more than 80 peer reviewed journal articles and helds 20 patents.
Humabs was acquired by Vir Biotechnology in 2017 to become its subsidiary in Bellinzona, Switzerland.
Dr. Davide Corti is now Senior Vice President, leading Antibody Research at Vir.